Susceptibility of Rifampicin-Isoniazid Resistant Mycobacterium Tuberculosis Isolates Against Levofloxacin by Alvin Hartanto Kurniawan et al.
ORIGINAL ARTICLE 
Bali Medical Journal (Bali Med J) 2016, Volume 5, Number 1: 7-11
P-ISSN.2089-1180, E-ISSN.2302-2914




Background: Tuberculosis (TB) is a high burden disease in Indonesia 
with multidrug-resistant (MDR) TB incidence started to increase. 
Treatment success of MDR-TB globally was low in number than it was 
targeted which was especially caused by fluoroquinolone resistance. 
One of the fluoroquinolone is levofloxacin, an antibiotic that has been 
widely used irrationally as antimicrobial treatment. Therefore, this 
study investigated the sensitivity and MBC of MDR Mycobacterium 
tuberculosis isolates against Levofloxacin.
Method: The susceptibility test for MDR-Mycobacterium tuberculosis 
on levofloxacin by standard method with levofloxacin were on 
concentrations 0,5 μg/ml, 1 μg/ml, and 2 μg/ml. Sample of 8 
strains MDR-Mycobacterium tuberculosis were cultured with each 
concentrations on Middlebrook 7H9 for 1 week incubation. Next, 
each of the incubated concentration was subcultured on solid media 
Middlebrook 7H10 for 3 weeks incubation. Colonized agar plates after 
3 weeks incubation were confirmed with acid-fast stain.
Results: On MB 7H10 with levofloxacin concentration 2 μg/ml showed 
bactericidal effect 100% by no MDR Mycobacterium tuberculosis 
colony grew (0/8) while the MB 7H10 with levofloxacin concentration 
1 μg/ml and 0,5 μg/ml showed the bactericidal effect 37,5% and 
25% respectively. The colonized agar plate implied that the MDR 
Mycobacterium tuberculosis with levofloxacin concentration 1 μg/ml 
(5/8) and 0,5 μg/ml (6/8) grew well.
Conclusion: Levofloxacin concentration 2 μg/ml was susceptible 
on MDR Mycobacterium tuberculosis. The concentration 2 μg/ml of 
levofloxacin could be considered asMBC.
Keywords: Tuberculosis; Mycobacterium tuberculosis; Levofloxacin, Susceptibility Test
Cite this Article: Kurniawan, A.H., Mertaniasih, N.M., Soedarsono. 2016. Susceptibility of rifampicin-isoniazid resistant mycobacterium 
tuberculosis isolates against levofloxacin. Bali Medical Journal 5(1): 7-11. DOI: 10.15562/bmj.v5i1.184
INTRODUCTION
Tuberculosis (TB) is one of high burden diseases 
in Indonesia with incidence in 2014, according to 
WHO global report in 2015, is about 1 000 000 
cases, the second most in the world after India, with 
mortality rate about 100 000 cases.1 The number of 
TB incidence in 2014 is hugely increased, compared 
to 2013, which was only about 460 000 cases and 
mortality rate approximately 68 000 cases.2
The other problem is antibiotic resistance. 
Antibiotic resistance has been a major problem in 
antibiotic era that is caused by the bacteria adap-
tation and mutation to modify target of antibiotic 
action on either enzymes or genes.3
Antibiotic resistance is also occurred on 
Mycobacterium tuberculosis. Resistant to first 
line agents especially rifampicin and isoniazid, 
Mycobacterium tuberculosis is going to be multi-
drug-resistant (MDR) Mycobacterium tubercu-
losis. Resistant to second line agents primarily 
fluoroquinolone or injected drug aminoglycoside, 
MDR Mycobacterium tuberculosis is going to be 
extremely drug resistant (XDR) Mycobacterium 
tuberculosis.4
Indonesia is one of 27 high MDR-TB burden 
countries with new MDR-TB incidences in 2014 
are sub nationally reported about 1.9% of every new 
TB incidences while 12% of TB cases in Indonesia 
were reported on retreatment of MDR- TB cases. 
Another major problem is the treatment outcome 
of MDR-TB. WHO globally targeted that MDR-TB 
treatment success was at least 75%.1 While in 
Indonesia, the outcome was targeted about 80% for 
case detection rate and 75% for treatment success.1,5 
However, it was reported that the treatment for 
MDR-TB in Indonesia has been far below the target 
with merely 65% gave response effects and 56% 
managed to be success treatment.6 One of causes of 
MDR-TB treatment failure is drug resistance espe-
cially fluoroquinolone.7
Levofloxacin is one the newest generations of 
fluoroquinolone that has been widely accepted 
not only as MDR-TB treatment, but also as broad 
spectrum antibiotic for microbial treatment.7,8 
Levofloxacin is commonly used because it is a 
broad spectrum antibiotic with well tolerated side 
effect and good distribution that could reached 
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many tissues and body fluids.9 Despite its uses 
and benefits, unwise and irrational use of anti-
biotics will lead to bacterial resistance including 
Mycobacterium tuberculosis.3 Patients, who received 
levofloxacin during course of TB treatment, were 
more likely to get levofloxacin resistance during 
MDR TB treatment.10 This study aims to investigate 
sensitivity of MDR Mycobacterium tuberculosis 
isolates against levofloxacin and establish the mini-
mal bactericidal concentration of levofloxacin on 
MDR Mycobacteriumtuberculosis.
MATERIAL AND METHODS
The susceptibility test was carried out with 
experimental laboratory on standard method 
of in vitro indirect conventional tuberculosis 
test.11 The susceptibility test was held on Institute 
of Tropical Disease of Airlangga University, 
Surabaya- Indonesia.
Bacterial Strain
Rifampicin and isoniazid resistant strains of 
Mycobacterium tuberculosis randomly selected 
from isolate submitted to microbiology laboratory 
of Dr. Soetomo General Hospital on Surabaya. The 
isolate originated from sputum of patients with 
pulmonary MDR-TB. The Mycobacterium tuber-
culosis isolate with concentration 107 cfu/ml were 
diluted with Middlebrook (MB) 7H9 until to get 
105 cfu/ml suspension. The process was started by 
blending 107 cfu/ml concentration of Mycobacterium 
tuberculosis with vertex for 1  minute. Next, the 
Mycobacterium tuberculosis concentration was 
taken 500 μl by micropipette and diluted with 4.5 ml 
MB 7H9 to get 106 cfu/ml suspension. These steps 
repeated once again to get 105 cfu/mlsuspension.12
Levofloxacin Solution
Levofloxacin solution with concentration 
500 mg/100ml were diluted with sodium chloride 
0.9% to get levofloxacin solution final concentra-
tion 0.5 μg/ml, 1 μg/ml, and 2μg/ml.
Dilution Test
Sample of the 105 cfu/ml suspension of 
Mycobacterium tuberculosis was replicated 8 times 
for each of levofloxacin solution final concentra-
tion. The dilution test was carried out in broth 
medium MB 7H9 with 0.5 ml of the Mycobacterium 
tuberculosis suspension and 0.5 ml of levofloxacin 
solution from each concentration. One control 
media was made in broth medium MB 7H9 with 
0.5 ml of the Mycobacterium tuberculosis suspen-
sion and 0.5 ml of sodium chloride 0.9% without 
any levofloxacin solution. The 25 broth media MB 
7H9 were incubated for one week in incubation 
cabinet at 37°C and CO25%.
Subculture test
Each of the 25 incubated cultured broth media with 
Mycobacterium tuberculosis and levofloxacin were 
subculture on solid medium MB 7H10. The subcul-
ture process were done by took 100 μl of each incu-
bated cultured broth media with micropipette and 
transferred to the surface solid medium MB 7H10. 
The subculture solid media MB 7H10 were incubated 
for 3 weeks in incubation cabinet at 37°C and CO25%.
Analysis
Analysis of the susceptibility test was done visually 
macroscopic and microscopic. The macroscopic 
visual analysis on MB 7H9 media was done by 
comparing the turbidity between control medium 
and each of concentration medium. The macro-
scopic visual analysis on MB 7H10 media by 
finding colony that characterize as Mycobacterium 
tuberculosis colony which is rough, granular, and 
creamy white.13 The solid media that were grown 
with colony of Mycobacterium tuberculosis were 
analyzed microscopically with acid fast staining 
(Ziehl Neelsen).4 The concentration, which was 
qualified to be sensitive and have bactericidal effect 
on Mycobacterium tuberculosis, had to be no colony 
grew in all of 8 replication samples (99.9%).14
Figure 1  A The result of cultured Mycobacterium 
tuberculosis on MB 7H9 without any 
levofloxacin a) and with levofloxacin 
solution 2 μg/ml b), 1 μg/ml (c), and 0.5 
μg/ml (d) after 1 week incubation. B The 
result of subcultured Mycobacterium 
tuberculosis after 3 weeks incubation 
without levofloxacin on MB 7H10 that 
showed many colonies grew and C, D, 
E with levofloxacin 0.5 μg/ml which 
also showed 6 out of 8 samples grew 
colonies. 
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RESULTS
After 7 day of incubation in broth media MB 
7H9, samples and control were observed macro-
scopically by comparing the turbidity. The result 
is there were no differences in turbidity between 
samples and control (Figure 1A). Next, this study 
continued with subcultured each samples and 
a contol in solid media MB 7H10 for 3 weeks. 
The control showed many colonies with charac-
teristics as Mycobacterium tuberculosis colony 
which was rough, granular, and creamy white 
(Figure 1B) while the subcultured Mycobacterium 
tuberculosis with levofloxacin solution 0.5 μg/ml 
showed 6 out of 8  samples (6/8) grew colonies 
with characteristics as Mycobacterium tuberculosis 
colony (Figure 1C, 1D, and 1E). The subcultured 
with 1 μg/ml showed 5 out of 8 samples (5/8) grew 
colonies that characterized as Mycobacterium 
tuberculosis colony (Figure 2A, 2B, 2C, and 2D) 
while the subcultured with 2  μg/ml pointed out 
no colony (0/8) that panned out grew on solid 
media MB  7H10 (Figure 2E, 2F, 2G, and 2H). 
The colony that grew on each solid media MB 
7H10 were stained with Ziehl Neelsen method 
to confirm the colonies were Mycobacterium 
tuberculosiscolonies.
DISCUSSION
With the increasing in number of MDR-TB inci-
dence in Indonesia and one major cause of it 
because of fluoroquinolone resistant, this study was 
to investigate sensitivity of the MDR Mycobacterium 
tuberculosis against levofloxacin with susceptibility 
test.1,7
Levofloxacin was chosen in this study because 
it was better than the other fluoroqionolone. 
The  other fluoroquinolone such as ciprofloxacin 
were reported very high in number while offloxa-
cin, which is the L-isomer of levofloxacin, was less 
bactericidal than levofloxacin. Gatifloxacin was 
avoided because of the side effect. Moxifloxacin, 
one of the newest generation of fluroquinolone, 
was less bactericidal and more potent to be resistant 
than levofloxacin.15
The susceptibility test was begun with dilution 
test on MB 7H9 with 1 week incubation. After 
1 week, observation was done visually by compar-
ing the turbidity between control and samples. The 
result was there was no difference of turbidity on 
both control and samples which was explained 
because Mycobacterium tuberculosis, unlike other 
common bacteria, needed 20 hours to replicate 
itself with heavily clumped. Therefore, common 
observation on turbidity in Mycobacterium tuber-
culosis dilution test was hardly done unless using 
some expensive reagants such as BACTEC or 
MB-7H12.16
Because of the undifferented turbidity, the next 
process was subculture. The media in the study 
was preferred MB 7H10 to Lowenstein-Jensen 
(LJ) because LJ is an egg-based solid media that 
much more potent to be contaminated and less 
sensitive than MB 7H10 which is using antibiotic.17 
Disadvantage of using MB 7H10 are incubation 
time that is shorter than LJ and the price that is 
more expensive than LJ.18
After 3 weeks incubation, the subculture on 
MDR Mycobacterium tuberculosis with levofloxa-
cin solution 0.5 μg/ml and 1 μg/ml on MB 7H10 
were colonized consecutively 75.00% and 62.50%. 
The result indicated that these concentrations were 
categorized as resistant because of inadequate 
bactericidal dose of levofloxacin solution that 
allowed several strain to adapt, mutate, and modify 
the target of antibiotic action. Contrarily on 2 μg/
ml that showed no colony implied that the concen-
tration was adequate dose so that no bacteria able 
to either adapt or mutate.4 The concentration 2 μg/
ml was categorized as sensitive in this study and 
the only concentration that had bactericidal effect 
because no colony grew on all thereplications.19
Comparation this study with other study, 
Angeby et al in 2010 represented levofloxacin, one 
of four fluoroquinolone that was used in the study, 
had critical minimal inhibitory concentration 
(MIC) on Mycobacterium tuberculosis was at 2 μg/
ml.20 Sanders et al in 2006 represented levofloxa-
cin critical concentration with BACTEC 460 and 
BACTEC MGIT 960 was at 2 μg/ml while with 
agar plate method was at 1 μg/ml.21 Niward et  al 
Figure 2  The result of subcultured Mycobacterium tuberculosis after 3 weeks 
incubation A, B, C, D with levofloxacin 1 μg/ml that showed 5 out 
of 8 samples grew colonies and E, F, G, H with levofloxacin 2 μg/ml 
that pointed out no colony grew.
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in 2016 showed in their study that levofloxacin 
1  μg/ml was resistant to Fluoroquinolone resis-
tant- Mycobacterium tuberculosis which resulted in 
increased MIC of levofloxacin (2-8 μg/ml).22 Ahmed 
et al in 2013 showed in their study in Pakistan that 
levofloxacin with 1 μg/ml on pre- XDR TB was 
almost completely resistant (91.20%).23 Kim et al in 
2013 with their study on some of Mycobacterium 
tuberculosis strains showed that on levofloxacin 
with concentration 2 μg/ml was sensitive to all 
strains.24
CONCLUSION
This study demonstrated that levofloxacin solution 
with concentration 2 μg/ml was susceptible against 
MDR Mycobacterium tuberculosis isolates and also 
the MBC of this study. Management of rational 
and wise antibiotic use especially levofloxacin is 
required to maintain the sensitivity of levofloxacin 
on Mycobacterium tuberculosis. Further studies are 
also needed to update the susceptibility of levoflox-
acin on Mycobacterium tuberculosis.
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